3 months Geron Stock Rallies More Than 60% in a Year: Here’s Why Zacks
FDA’s approval of GERN’s Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
XFDA’s approval of GERN’s Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.
XThe Stock Market News is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live trading analysis, opinions and forecasts on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds, rates and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.